These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 8133027)

  • 41. MHC class I molecule-restricted presentation of viral antigen in beta 2-microglobulin-deficient mice.
    Lehmann-Grube F; Dralle H; Utermöhlen O; Löhler J
    J Immunol; 1994 Jul; 153(2):595-603. PubMed ID: 8021497
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single amino acid replacements in an antigenic peptide are sufficient to alter the TCR V beta repertoire of the responding CD8+ cytotoxic lymphocyte population.
    Kalergis AM; Ono T; Wang F; DiLorenzo TP; Honda S; Nathenson SG
    J Immunol; 1999 Jun; 162(12):7263-70. PubMed ID: 10358174
    [TBL] [Abstract][Full Text] [Related]  

  • 43. T-splenocytes from non-obese diabetic mice binding to xenogeneic pancreatic beta-cells in vitro. Implication of the alpha/beta T-cell receptor and of major histocompatibility complex class II molecules from target cells.
    Martignat L; Feve B; Ouary M; Pogu S; Charbonnel B; Saï P
    J Autoimmun; 1993 Dec; 6(6):753-69. PubMed ID: 8155255
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biased T cell receptor usage by Ld-restricted, tum- peptide-specific cytotoxic T lymphocyte clones.
    Solheim JC; Alexander-Miller MA; Martinko JM; Connolly JM
    J Immunol; 1993 Feb; 150(3):800-11. PubMed ID: 8380825
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells.
    Zijlstra M; Bix M; Simister NE; Loring JM; Raulet DH; Jaenisch R
    Nature; 1990 Apr; 344(6268):742-6. PubMed ID: 2139497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Insight into the mechanism of TCR-V beta 8+/CD8+ T cell-mediated MOPC-315 tumor eradication.
    Mokyr MB; Prokhorova A; Rubin M; Bluestone JA
    J Immunol; 1994 Oct; 153(7):3123-34. PubMed ID: 8089490
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sufficiency of the CD8+ T cell lineage to mount an effective tumoricidal response to syngeneic tumor-bearing novel class I MHC antigens.
    Fan ST; Edgington TS
    J Immunol; 1989 Dec; 143(12):4287-91. PubMed ID: 2531780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Origin of a T cell clone with a mismatched combination of MHC restriction and coreceptor expression.
    Suzuki H; Eshima K; Takagaki Y; Hanaoka S; Katsuki M; Yokoyama M; Hasegawa T; Yamazaki S; Shinohara N
    J Immunol; 1994 Nov; 153(10):4496-507. PubMed ID: 7525706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene.
    Hui KM; Sim T; Foo TT; Oei AA
    J Immunol; 1989 Dec; 143(11):3835-43. PubMed ID: 2584720
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Precursor CTL specific for retrovirus-induced T lymphoma are found at high frequency in unprimed syngeneic mice.
    Moutschen MP; Shan H; Giantonio BJ; Bookman MA
    Cell Immunol; 1994 Feb; 153(2):367-77. PubMed ID: 7907004
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Skin graft rejection elicited by beta 2-microglobulin as a minor transplantation antigen involves multiple effector pathways: role of Fas-Fas ligand interactions and Th2-dependent graft eosinophil infiltrates.
    Surquin M; Le Moine A; Flamand V; Nagy N; Rombaut K; Demoor FX; Stordeur P; Salmon I; Guéry JC; Goldman M; Abramowicz D
    J Immunol; 2002 Jul; 169(1):500-6. PubMed ID: 12077281
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rejection of mouse sarcoma cells after transfection of MHC class II genes.
    Ostrand-Rosenberg S; Thakur A; Clements V
    J Immunol; 1990 May; 144(10):4068-71. PubMed ID: 2332639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TCR-independent killing of B cell malignancies by anti-third-party CTLs: the critical role of MHC-CD8 engagement.
    Lask A; Goichberg P; Cohen A; Goren-Arbel R; Milstein O; Aviner S; Feine I; Ophir E; Reich-Zeliger S; Hagin D; Klein T; Nagler A; Berrebi A; Reisner Y
    J Immunol; 2011 Aug; 187(4):2006-14. PubMed ID: 21753148
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of MHC class I and CD8 cell deficiency on experimental autoimmune myasthenia gravis pathogenesis.
    Shenoy M; Kaul R; Goluszko E; David C; Christadoss P
    J Immunol; 1994 Dec; 153(11):5330-5. PubMed ID: 7963585
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Two distinct populations of primary cytotoxic cells infiltrating into allografted tumor rejection sites: infiltration of macrophages cytotoxic against allografted tumor precedes that of multiple sets of cytotoxic T lymphocytes with distinct specificity to alloantigens.
    Yoshida R; Matsuura A; Einaga K; Ushio Y; Yamamoto N; Yoneda Y
    Microbiol Immunol; 1997; 41(2):149-59. PubMed ID: 9087957
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Major histocompatibility complex class I-specific and -restricted killing of beta 2-microglobulin-deficient cells by CD8+ cytotoxic T lymphocytes.
    Glas R; Franksson L; Ohlén C; Höglund P; Koller B; Ljunggren HG; Kärre K
    Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11381-5. PubMed ID: 1454824
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recovery of activated cytotoxic T cells from minor H incompatible tumor graft rejection sites.
    Ksander BR; Streilein JW
    J Immunol; 1989 Jul; 143(2):426-31. PubMed ID: 2500481
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Specific associations of fluorescent beta-2-microglobulin with cell surfaces. The affinity of different H-2 and HLA antigens for beta-2-microglobulin.
    Hochman JH; Shimizu Y; DeMars R; Edidin M
    J Immunol; 1988 Apr; 140(7):2322-9. PubMed ID: 2450918
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Beta 2-microglobulin restriction of antigen presentation.
    Pérarnau B; Siegrist CA; Gillet A; Vincent C; Kimura S; Lemonnier FA
    Nature; 1990 Aug; 346(6286):751-4. PubMed ID: 1697039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Skin graft rejection by beta 2-microglobulin-deficient mice.
    Zijlstra M; Auchincloss H; Loring JM; Chase CM; Russell PS; Jaenisch R
    J Exp Med; 1992 Apr; 175(4):885-93. PubMed ID: 1552287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.